Deutsche Bank AG Sells 3,624 Shares of Krystal Biotech, Inc. $KRYS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Deutsche Bank AG cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 14.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 21,737 shares of the company's stock after selling 3,624 shares during the quarter. Deutsche Bank AG owned about 0.08% of Krystal Biotech worth $3,919,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. LPL Financial LLC raised its holdings in shares of Krystal Biotech by 156.8% in the fourth quarter. LPL Financial LLC now owns 2,946 shares of the company's stock valued at $462,000 after purchasing an additional 1,799 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Krystal Biotech by 21.3% in the fourth quarter. Wells Fargo & Company MN now owns 16,928 shares of the company's stock valued at $2,652,000 after purchasing an additional 2,972 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after purchasing an additional 121 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Krystal Biotech by 5.7% in the fourth quarter. Bank of Montreal Can now owns 3,325 shares of the company's stock valued at $521,000 after purchasing an additional 179 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at approximately $15,989,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider owned 1,508,056 shares in the company, valued at approximately $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Krystal Biotech Stock Performance

KRYS traded up $4.79 during trading hours on Friday, reaching $150.49. The company's stock had a trading volume of 246,954 shares, compared to its average volume of 428,473. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84. The company's 50-day moving average is $144.22 and its 200-day moving average is $154.55. The firm has a market cap of $4.36 billion, a PE ratio of 30.59 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million. Equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday. Citigroup reiterated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America cut their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Guggenheim cut their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Chardan Capital cut their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of "Buy" and an average target price of $210.38.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).